#SSc16 – Scleroderma News Top Articles Selection for the Congress

The 4th Systemic Sclerosis World Congress will take place in Lisbon, Portugal, from 18th to 20th February and Scleroderma News will be covering the whole event. Even though this is a systemic sclerosis (SSc) congress, a lot will be discussed about pulmonary arterial hypertension (PAH), which is considered a leading cause of mortality among systemic scleroderma patients.

Therefore, we decided to chose one article per satellite symposium that Scleroderma News team is  planning to cover. Here are the articles:

1. Bayer’s Adempas For CTEPH, PAH Confirmed Safe & Effective in Long-Term Studies

Findings collected during more than two years confirming the safety and efficacy of Bayer’s Adempas® (riociguat) in treating either inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), and patients with pulmonary arterial hypertension (PAH) were recently presented at the European Respiratory Society (ERS) Congress.

Read the article here: http://bit.ly/1olivPw

2. Effective Screening Models for Pulmonary Arterial Hypertension Diagnosis in Systemic Sclerosis Patients

A recent study published in the journal Arthritis Research & Therapy analyzed different prediction algorithms for the efficient diagnosis of pulmonary arterial hypertension (PAH) in patients with systemic sclerosis.

Read the article here: http://bit.ly/1oliHhH

3. Reata’s Bardoxolone Methyl as PAH Therapy Shows Promise in Initial Phase 2 Data

Irving, Texas-based Reata Pharmaceuticals, Inc. announced initial data from the LARIAT (A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension) trial (ClinicalTrials.gov Identifier: NCT02036970), evaluating bardoxolone methyl in pulmonary arterial hypertension (PAH) patients at the annual meeting of the 2015 American College of Chest Physicians (CHEST), running from October 25 to 28 at the Palais des Congrès de Montrèal Convention Center.

Read the article here: http://bit.ly/1PQhbQ4

4. Gilead Announces Encouraging Results For Combined Letairis/Tadalafil Therapy For Pulmonary Arterial Hypertension

Gilead Sciences, Inc. recently announced the publication of data in The New England Journal of Medicine concerning the AMBITION trial evaluating the combination therapy of Letairis® (ambrisentan) and tadalafil for pulmonary arterial hypertension (PAH). The AMBITION trial (NCT01178073) is a multicenter, randomized, double-blind Phase 3 study developed in collaboration with GlaxoSmithKline (GSK). The study is entitled “Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.”

Read the article here: http://bit.ly/1olkuDG